Caratterizzazione del profilo neurochimico, neuropatologico e neourofarmacologico di un modello sperimentale di glaucoma acuto
Mostra/ Apri
Creato da
Cavaliere,Federica
Morrone,Luigi Antonio
Bagetta,Giacinto
Metadata
Mostra tutti i dati dell'itemDescrizione
Formato
/
Dottorato di ricerca in Farmacologia e Biochimica della Morte Cellulare, XXII Ciclo, a.a. 2009-2010; Glaucoma is a leading cause of irreversibile blindness characterized by the progressive
loss of retinal ganglion cells (RGCs). Elevated intraocular pressure is a major risk factor for
glaucoma; however, medical therapies aimed to reduce intraocular pressure, are not
always successful blocking the glaucoma‐associated retinal degeneration. This
observation suggests that mechanisms other than intraocular pressure are also implicated
in glaucomatous neurodegeneration. Experimental evidences suggest that alteration of
glutamate homeostasis contributes to retinal dysfunction and neuropathy. However, the
involvement of excitotoxicity in RGCs loss is still controversial. Therefore, the aim of the
present study was to investigate the modulation of intravitreal glutamate levels in high
intraocular pressure (IOP) induced ischemia, an established animal model that
recapitulates features of acute angle closure glaucoma. Using this experimental model we
monitored extracellular glutamate in the vitreous of rat before, during and after high IOPinduced
ischemia. A significant increase of extracellular glutamate occurred during
reperfusion, 10 and 150 minutes after ischemia. In our experimental setting, calpain
activation is detected in the retina explants early after ischemia. Excess activation of
calpain caused deleterious effects on RGCs, in fact we have observed 25.9% loss of cells in
the RGCs layer at 7 days of the reperfusion. A pre‐treatment with coenzyme Q10
prevented retinal ganglion cells loss and inhibited the increase of glutamate observed in
the vitreous during reperfusion. In addition, systemic pre‐treatment with 17α and 17β‐ estradiol, endowed with neuroprotective and antioxidant properties, minimized the
elevation of glutamate observed during the reperfusion period. The reported effects
seem to be only in part mediated by the activation of the estrogen receptor, since a pretreatment
with ICI 182‐780, a specific estrogen receptor antagonist, partially counteracts
the effect afforded by the estrogen in the early phase of reperfusion. In order to
investigate the mechanisms supporting the observed increase of extracellular glutamate
levels we performed ex‐vivo experiments using synaptosomes prepared from the retina
of rats subjected to high IOP‐induced ischemia. Continuous superfusion of synaptosomes
allowed a direct measurement of release and mechanisms involved. These data obtained
indicated a reduced involvement of glutamate transporters in the mechanisms of release
induced by KCl 15 mM in ischemic synaptosomes. In addition, in the same experimental
conditions also the uptake is reduced. This is supported by reduced expression of the
neuronal trasporter GLT1.
Altogether these data, straighten the role of glutamate and oxidative stress in ischemiainduced
RGCs death and demonstrate that the observed increase of intravitreal
glutamate is associated to a reduction of the uptake and GLT1 expression.; Università della calabriaSoggetto
Farmacologia; Glaucoma
Relazione
BIO/14;